Table 2.
Two-way interactions between TLR4 and MyD88 polymorphisms in the risk of CAD.
| TLR4 | Genotypes | Number of Participants | MyD88 rs7744 | |||
|---|---|---|---|---|---|---|
| AA | AG + GG | AA + AG | GG | |||
| rs10116253 | TC + CC | No. of controls/cases | 123/101 | 179/169 | 258/242 | 44/28 |
| OR (95% CI) | 1.0 (ref.) | 1.052 (0.599–1.848) | 1.0 (ref.) | 0.715 (0.427–1.197) | ||
| TT | No. of controls/cases | 51/56 | 71/98 | 101/128 | 21/26 | |
| OR (95% CI) | 1.158 (0.608–2.207) | 1.561 (0.844–2.887) | 1.313 (0.951–1.812) | 1.406 (0.762–2.592) | ||
| p = 0.654, OR (95% CI) = 1.148 (0.627–2.104) | p = 0.322, OR (95% CI) = 1.517 (0.665–3.463) | |||||
| CC | No. of controls/cases | 31/29 | 51/42 | 67/67 | 15/4 | |
| OR (95% CI) | 1.0 (ref.) | 0.859 (0.433–1.702) | 1.0 (ref.) | 0.338 (0.103–1.106) | ||
| TC + TT | No. of controls/cases | 143/128 | 143/225 | 288/303 | 54/50 | |
| OR (95% CI) | 0.982 (0.558–1.728) | 1.290 (0.739–2.252) | 1.078 (0.735–1.581) | 1.121 (0.651–1.931) | ||
| p = 0.347, OR (95% CI) = 1.423 (0.682–2.966) | p = 0.065, OR (95% CI) = 3.231 (0.929–11.236) | |||||
| rs10983755 | GA + AA | No. of controls/cases | 94/76 | 141/130 | 203/184 | 32/22 |
| OR (95% CI) | 1.0 (ref.) | 1.110 (0.749–1.644) | 1.0 (ref.) | 0.774 (0.429–1.395) | ||
| GG | No. of controls/cases | 80/81 | 109/137 | 156/186 | 33/32 | |
| OR (95% CI) | 1.214 (0.781–1.887) | 1.595 (1.061–2.396) | 1.292 (0.959–1.741) | 1.139 (0.667–1.945) | ||
| p = 0.612, OR (95% CI) = 1.158 (0.657–2.042) | p = 0.728, OR (95% CI) = 1.153 (0.517–2.570) | |||||
| AA | No. of controls/cases | 14/14 | 24/22 | 30/35 | 8/1 | |
| OR (95% CI) | 1.0 (ref.) | 0.890 (0.312–2.541) | 1.0 (ref.) | 0.125 (0.013–1.217) | ||
| GA + GG | No. of controls/cases | 160/143 | 226/245 | 325/335 | 61/53 | |
| OR (95% CI) | 0.997 (0.453–2.195) | 1.287 (0.587–2.822) | 0.947 (0.562–1.596) | 0.908 (0.471–1.752) | ||
| p = 0.777, OR (95% CI) = 1.156 (0.424–3.157) | p = 0.074, OR (95% CI) = 7.346 (0.823–65.536) | |||||
| rs11536889 | GG | No. of controls/cases | 100/99 | 170/156 | 224/221 | 46/34 |
| OR (95% CI) | 1.0 (ref.) | 0.930 (0.653–1.323) | 1.0 (ref.) | 0.793 (0.485–1.297) | ||
| GC + CC | No. of controls/cases | 74/58 | 80/111 | 135/149 | 19/20 | |
| OR (95% CI) | 0.782 (0.501–1.220) | 1.395 (0.934–2.085) | 1.123 (0.828–1.522) | 1.258 (0.640–2.471) | ||
| p = 0.024, OR (95% CI) = 1.928 (1.089–3.413) | p = 0.436, OR (95% CI) = 1.399 (0.601–3.258) | |||||
| GG + GC | No. of controls/cases | 165/152 | 238/247 | 345/352 | 58/47 | |
| OR (95% CI) | 1.0 (ref.) | 1.143 (0.854–1.529) | 1.0 (ref.) | 0.851 (0.558–1.298) | ||
| CC | No. of controls/cases | 9/5 | 12/20 | 14/18 | 7/7 | |
| OR (95% CI) | 0.589 (0.192–1.810) | 1.884 (0.876–4.052) | 1.237 (0.598–2.561) | 1.113 (0.379–3.267) | ||
| p = 0.119, OR (95% CI) = 2.943 (0.756–11.454) | p = 0.909, OR (95% CI) = 1.082 (0.280–4.181) | |||||
Notes: All tests were adjusted by age, sex, hypertension, hyperglycemia, hyperlipidemia and H. pylori infection. Statistically significant interaction was highlighted in bold (p value for interaction <0.05). CAD: coronary artery disease; TLR4: toll-like receptor 4; MyD88: myeloid differentiation factor 88; OR: odds ratio; CI: confidence interval; ref.: reference.